ZINC propionate | 90529-81-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ZINC propionate
• 英文别名: zinc;propanoate
• CAS: 90529-81-0
• 化学式: C6H10O4Zn
• 分子量: 211.5
• InChiKey: XDWXRAYGALQIFG-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -1.71
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  4

ADMET

代谢

锌可以通过肺部、皮肤和胃肠道进入人体。肠道对锌的吸收由锌载体蛋白CRIP控制。锌还与金属硫蛋白结合，帮助防止过量锌的吸收。锌广泛分布并在所有组织和组织液中找到，特别是在肝脏、胃肠道、肾脏、皮肤、肺、大脑、心脏和胰腺中。在血液中，锌存在于红细胞中的碳酸酐酶结合，以及血浆中的白蛋白、α2-巨球蛋白和氨基酸结合。白蛋白和氨基酸结合的锌可以扩散穿过组织膜。锌通过尿液和粪便排出体外。

Zinc can enter the body through the lungs, skin, and gastrointestinal tract. Intestinal absorption of zinc is controlled by zinc carrier protein CRIP. Zinc also binds to metallothioneins, which help prevent absorption of excess zinc. Zinc is widely distributed and found in all tissues and tissues fluids, concentrating in the liver, gastrointestinal tract, kidney, skin, lung, brain, heart, and pancreas. In the bloodstream zinc is found bound to carbonic anhydrase in erythrocytes, as well as bound to albumin, _2-macroglobulin, and amino acids in the the plasma. Albumin and amino acid bound zinc can diffuse across tissue membranes. Zinc is excreted in the urine and faeces. (L49)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 毒性总结

缺铁性贫血是由于锌的过量吸收抑制了铜和铁的吸收，这很可能是通过肠道粘膜细胞的竞争性结合实现的。铜和锌与铜锌超氧化物歧化酶的不平衡水平已被与肌萎缩侧索硬化症（ALS）联系在一起。胃酸能溶解金属锌，生成腐蚀性的氯化锌，这可能会对胃壁造成损害。金属烟雾热被认为是对吸入锌的免疫反应。（L48, L49, A49）

Anaemia results from the excessive absorption of zinc suppressing copper and iron absorption, most likely through competitive binding of intestinal mucosal cells. Unbalanced levels of copper and zinc binding to Cu,Zn-superoxide dismutase has been linked to amyotrophic lateral sclerosis (ALS). Stomach acid dissolves metallic zinc to give corrosive zinc chloride, which can cause damage to the stomach lining. Metal fume fever is thought to be an immune response to inhaled zinc. (L48, L49, A49)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌物分类

对人类无致癌性（未列入国际癌症研究机构IARC清单）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 健康影响

长期接触锌会导致贫血、运动失调、乏力，并降低体内的好胆固醇水平。还认为它会导致胰腺和生殖损害。

Chronic exposure to zinc causes anemia, atazia, lethargy, and decreases the level of good cholesterol in the body. It is also believed to cause pancreatic and reproductive damage. (L49)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 暴露途径

口服（L49）；吸入（L49）；皮肤给药（L49）

Oral (L49) ; inhalation (L49) ; dermal (L49)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 症状

大量摄入锌会导致胃痉挛、恶心和呕吐。急性吸入大量锌会导致金属烟雾热，其特点是寒战、发热、头痛、乏力、鼻和喉咙干燥、胸痛和咳嗽。锌与皮肤的接触会导致皮肤刺激。

Ingestion of large doses of zinc causes stomach cramps, nausea, and vomiting. Acute inhalation of large amounts of zinc causes metal fume fever, which is characterized by chills, fever, headache, weakness, dryness of the nose and throat, chest pain, and coughing. Dermal contact with zinc results in skin irritation. (L49)

来源:Toxin and Toxin Target Database (T3DB)

吸收、分配和排泄

静脉注射锌后，锌会分布到红细胞、血浆和白细胞中；血液中大约80%的锌存在于红细胞中，12-20%在血浆中，大约3%在白细胞中。血浆和红细胞之间存在锌的动态交换。吸入锌盐的尘埃会在肺部暂时积聚，然后被吸收到血液中。通过皮肤吸收的锌或其盐分很少。大约80%的静脉注射锌通过粪便排出，这表明锌有一个肠肝循环。在人体中，大约10%的吸收锌通过尿液排出，在热带气候中，每天大约有2-3毫克的锌通过汗水丢失。/可溶性锌化合物/

Upon intravenous injection zinc is distributed to erythrocytes, plasma, and leukocytes; about 80% of the zinc present in the blood is found in the erythrocytes, 12-20% in the plasma, and about 3% in the leukocytes. ... There is a dynamic exchange of zinc between plasma and erythrocytes. Inhalation of dusts of zinc salts results in a transient accumulation in the lung before its absorption into the blood. There is little absorption of zinc or its salts through the skin. ... About 80% of parenterally administered zinc is excreted in the feces, suggesting an enterohepatic circulation for zinc. In humans, about 10% of the absorbed zinc is excreted in the urine, and in tropical climates about 2-3 mg zinc/day may be lost in sweat. /Soluble zinc compounds/

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为产物：
  描述：

  丙酸 、 Zinc Oxide 生成 ZINC propionate
  参考文献：
  名称：

  Process for producing metal carboxylates for use as animal feed

  摘要：

  本发明揭示了一种制备具有公式M(CH.sub.3 (CH.sub.2).sub.xCOO.sup.-).sub.2的二价金属羧酸盐的方法，其中M是二价金属阳离子，锌（Zn.sup.+2）或铜（Cu.sup.+2），x为零或1。在这个过程中，无水C.sub.2-C.sub.3羧酸与碱性二价金属化合物混合，该化合物是Zn.sup.+2或Cu.sup.+2的氧化物，氢氧化物或碳酸盐，在没有添加溶剂或其他稀释剂的情况下。所生产的二价金属羧酸盐被用作动物饲料中微量元素的生物学有效和经济的来源。

  公开号：

  US05795615A1

文献信息

• Use of Rylene Derivatives as Photosensitizers in Solar Cells
  申请人：Pschirer Neil Gregory

  公开号：US20080269482A1

  公开（公告）日：2008-10-30

  Use of rylene derivatives I with the following definition of the variables: X together both —COOM; Y a radical -L-NR 1 R 2 (y1) -L-Z-R 3 (y2) the other radical hydrogen; together both hydrogen; R is optionally substituted (het)aryloxy, (het)arylthio; P is —NR 1 R 2 ; B is alkylene; optionally substituted phenylene; combinations thereof; A is —COOM; —SO 3 M; —PO 3 M 2 ; D is optionally substituted phenylene, naphthylene, pyridylene; M is hydrogen; alkali metal cation; [NR 5 ] 4 + ; L is a chemical bond; optionally indirectly bonded, optionally substituted (het)arylene radical; R 1 , R 2 are optionally substituted (cyclo)alkyl, (het)aryl; together optionally substituted ring comprising the nitrogen atom; Z is —O—; —S—; R 3 is optionally substituted alkyl, (het)aryl; R′ is hydrogen; optionally substituted (cyclo)alkyl, (het)aryl; R 5 is hydrogen; optionally substituted alkyl (het)aryl; m is 0, 1, 2; n, p m=0: 0, 2, 4 where: n+p=2, 4, if appropriate 0; m=1: 0, 2, 4 where: n+p=0, 2, 4; m=2: 0, 4, 6 where: n+p=0, 4, 6, or of mixtures thereof as photosensitizers in solar cells.

  使用以下变量定义的莱伦衍生物I的用途： X一起 两者都是-COOM; Y是一个基团 -L-NR 1 R 2 (y1) -L-Z-R 3 (y2) 另一个基团是氢; 一起 两者都是氢; R可选择地被取代为(het)芳氧基，(het)芳基硫基; P是-NR 1 R 2 ; B是烷基; 可选择地被取代的苯基; 它们的组合; A是-COOM; -SO 3 M; -PO 3 M 2 ; D可选择地被取代为苯基，萘基，吡啶基; M是氢; 碱金属阳离子; [NR 5 ] 4 + ; L是化学键; 可选择地间接键合，可选择地被取代的(het)芳基基团; R 1 ，R 2 可选择地被取代的(环)烷基，(het)芳基; 一起可选择地被取代的环，其中包括氮原子; Z是-O-; -S-; R 3 可选择地被取代的烷基，(het)芳基; R′是氢; 可选择地被取代的(环)烷基，(het)芳基; R 5 是氢; 可选择地被取代的烷基(het)芳基; m为0, 1, 2; n, p, m=0: 0, 2, 4其中：n+p=2, 4，如果适用为0; m=1: 0, 2, 4其中：n+p=0, 2, 4; m=2: 0, 4, 6其中：n+p=0, 4, 6， 或者作为太阳能电池中的光敏剂的混合物。
• [EN] ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS<br/>[FR] ANTI-INFECTIEUX A BASE D'ISOTHIAZOLOQUINOLONES ET DE SELS CORRESPONDANTS
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2005019228A1

  公开（公告）日：2005-03-03

  The invention provides compounds and salts of Formula (I) and Formula (II): which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula (I) and Formula (II). The variables A1, R2, R3, R5, R6, R7, A8 and R9 are defined herein. Certain compounds of Formula (I) and Formula (II) disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula (I) or Formula (II) and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula (I) or Formula (II) as the only active agent or may contain a combination of a compound of Formula (I) or Formula (II) and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

  本发明提供了具有抗菌活性的公式(I)和公式(II)的化合物及盐类：本发明还提供了用于制造公式(I)和公式(II)化合物的新的合成中间体。变量A1、R2、R3、R5、R6、R7、A8和R9在此文中定义。本文披露的某些公式(I)和公式(II)化合物是细菌DNA合成和细菌复制的强效和选择性抑制剂。本发明还提供了含有一种或多种公式(I)或公式(II)化合物以及一种或多种载体、辅料或稀释剂的抗菌组合物，包括药物组合物。这样的组合物可以只含有公式(I)或公式(II)的化合物作为唯一的活性成分，也可以含有公式(I)或公式(II)的化合物与一种或多种其他活性成分的组合。本发明还提供了用于治疗动物微生物感染的方法。
• Metal oxide particle and its uses
  申请人：Takeda Mitsuo

  公开号：US20070154561A1

  公开（公告）日：2007-07-05

  An object of the present invention is to provide a metal oxide particle which exercises more excellent ultraviolet absorbency as a matter of course and combines therewith merits of, for example, either being shifted in ultraviolet absorption edge toward the longer wavelength side and being excellent also in the absorption efficiency of a long-wavelength range of ultraviolet rays, or having good transparency and, for example, even in cases where added into or coated onto substrates, not damaging the transparency or hue of the substrates. As a means of achieving this object, a metal oxide particle according to the present invention is a metal oxide particle such that a hetero-element is contained in a particle comprising an oxide of a specific metal element (M), wherein the metal oxide particle is: 1) a metal oxide particle in the form of a fine particle wherein the hetero-element is at least one specific metal element (M′); 2) a metal oxide particle wherein the hetero-element includes at least two specific metal elements (M′); 3) a metal oxide particle wherein: the hetero-element is a more specified metal element (M′) and at least a part thereof is 2 in valence; or the metal element (M) is a more specified metal element and the metal oxide particle is in a specific range in crystal grain diameter in the vertical direction to each of the (002) plane and the (100) plane; or 4) a metal oxide particle wherein: the hetero-element is at least one specific nonmetal element and an acyl group is contained in the particle; or the hetero-element includes at least two specific nonmetal elements; or the hetero-element is at least one specific nonmetal element and a component derived from a metal element (M′) other than the metal element (M) is contained in the particle.

  本发明的目的是提供一种金属氧化物微粒，它自然具有更优异的紫外线吸收性能，并结合了例如向长波长侧移动紫外线吸收边缘且在紫外线长波长范围的吸收效率也极佳的优点，或者具有良好的透明性，例如，即使添加到或涂覆在基材上，也不会损害基材的透明性或色调。为实现这一目的，根据本发明的金属氧化物微粒是一种特定金属元素（M）的氧化物的微粒中包含异元素金属氧化物微粒，其中该金属氧化物微粒是：1）一种微粒形式的细小金属氧化物微粒，其中异元素至少是一种特定金属元素（M′）；2）一种金属氧化物微粒，其中异元素包括至少两种特定金属元素（M′）；3）一种金属氧化物微粒，其中：异元素是一种更特定的金属元素（M′）且至少其部分是二价的；或者金属元素（M）是一种更特定的金属元素，且金属氧化物微粒在垂直于（002）面和（100）面的晶体粒度直径在特定范围内；或者4）一种金属氧化物微粒，其中：异元素至少是一种特定非金属元素，且微粒中包含酰基；或者异元素包括至少两种特定非金属元素；或者异元素至少是一种特定非金属元素，且微粒中包含来自金属元素（M′）以外的金属元素的成分。
• [EN] TREATMENT OF INFECTIONS<br/>[FR] TRAITEMENT D'INFECTIONS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2020064844A1

  公开（公告）日：2020-04-02

  The present invention relates among other aspects to a conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said conjugate or its pharmaceutically acceptable salt for use in a method of preventing or treating an infection, wherein said conjugate is water-insoluble and comprises a polymeric moiety -Z to which a plurality of moieties -L2-X0D-L1-D are covalently conjugated, wherein each -D is independently an antibiotic moiety; each -L1- is independently a linker moiety to which -D is covalently and reversibly conjugated; each -X0D- is independently absent or a linkage and each -L2- is independently either a chemical bond or a spacer moiety.

  本发明涉及一种共轭物或其药用可接受的盐，或包含所述共轭物或其药用可接受的盐的药物组合物，用于预防或治疗感染的方法，其中所述共轭物不溶于水，包括一个聚合物基团-Z，其中多个基团-L2-X0D-L1-D以共价结合方式共轭，其中每个-D独立地是抗生素基团；每个-L1-独立地是连接基团，与-D以共价和可逆方式结合；每个-X0D-独立地不存在或是一个连接，每个-L2-独立地是化学键或间隔基团。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。